Skip to main content
. 2023 Jun 15;13(7):1517–1534. doi: 10.1007/s13555-023-00942-y
Download video file (43.6MB, mp4)

Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study (MP4 44681 KB)